G, W., J, Z., M, Z., Q, W., B, C., Y, H., & K, L. (2019). Ferumoxytol and CpG oligodeoxynucleotide 2395 synergistically enhance antitumor activity of macrophages against NSCLC with EGFRL858R/T790M mutation. Dove Medical Press.
Chicago Style (17th ed.) CitationG, Wang, Zhao J, Zhang M, Wang Q, Chen B, Hou Y, and Lu K. Ferumoxytol and CpG Oligodeoxynucleotide 2395 Synergistically Enhance Antitumor Activity of Macrophages Against NSCLC with EGFRL858R/T790M mutation. Dove Medical Press, 2019.
MLA (8th ed.) CitationG, Wang, et al. Ferumoxytol and CpG Oligodeoxynucleotide 2395 Synergistically Enhance Antitumor Activity of Macrophages Against NSCLC with EGFRL858R/T790M mutation. Dove Medical Press, 2019.
Warning: These citations may not always be 100% accurate.